Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Chinese trials in first-line NSCLC and colorectal cancer are imminent.
But there are no efficacy data, and the mechanism has a mountain to climb.
BPI-572270 enters clinical trials.
The company has ditched a trial of drebuxelimab plus ivonescimab.
CRB-601 and PF-06940434 fall by the wayside.
A new company will develop “next-generation mRNA” projects, amid another mRNA setback.
